The Improving Home Dialysis Act of 2026 (H.R. 8875) aims to enhance Medicare coverage for individuals undergoing dialysis at home. Starting January 1, 2028, the bill proposes to include two new services: (1) Staff-Assisted Home Dialysis Respite Care, providing temporary professional assistance during the initial 30 days of home dialysis or when patients face physical limitations, limited to 20 sessions per year; and (2) Renal Mental Health Services, offering up to four mental health sessions within the first 60 days of starting home dialysis. These additions are designed to support patients transitioning to home-based dialysis and address challenges they may encounter.
The National Kidney Foundation (NKF) and the American Society of Nephrology (ASN) have expressed strong support for H.R. 8875. The NKF highlighted the bill as a significant step toward making home dialysis more accessible, emphasizing its potential to help patients remain at home and reduce care disruptions. Similarly, ASN President Dr. Samir M. Parikh praised the legislation for expanding options for Americans with kidney failure and commended Representative Carol Miller's commitment to innovative kidney care solutions.
As of now, there is limited media coverage presenting negative reactions to H.R. 8875. Potential concerns that may arise include the financial implications of expanding Medicare coverage without specified funding, which could impact the program's budget. Additionally, the effectiveness of the proposed services in improving patient outcomes and the readiness of healthcare providers to implement these changes might be questioned. However, such critiques have not been prominently featured in current media reports.
The analysis of H.R. 8875: Improving Home Dialysis Act of 2026 reveals no direct industry overlaps between the sponsor Carol Miller's top donor industries and the subject matter of the bill. The lobbying activity in this policy area includes several undisclosed contributions from various groups, but none of these appear to directly connect to home dialysis or related healthcare services. The only significant disclosed lobbying amount is $600,000 from the National Electrical Contractors Association, Inc., which does not have a clear relevance to home dialysis. Therefore, the risk of conflict of interest appears low as there are no financial incentives from donors that would directly influence the legislation.
Organizations that lobbied on issues related to this bill's policy area.
| Client | Lobbying Firm | Amount |
|---|---|---|
| NATIONAL ELECTRICAL CONTRACTORS ASSOCIATION, INC. | NATIONAL ELECTRICAL CONTRACTORS ASSOCIATION, INC. | $600,000 |
| BSA, THE SOFTWARE ALLIANCE | TIM YEHL, LLC | $20,000 |
| ENVISION GROUP LLC | MR. ANDREW FUTEY | undisclosed |
| GESCONTI GROUP,INC. | GESCONTI GROUP,INC. | undisclosed |
| JOHN BRIAN LEDBETTER MISSIONS CORPORATION | JOHN BRIAN LEDBETTER MISSIONS CORPORATION | undisclosed |
| KASICH COMPANY | MARKQUEST | undisclosed |
| MARKQUEST | MARKQUEST | undisclosed |
| AMERICAN FINANCIAL SERVICES ASSOCIATION | MARKQUEST | undisclosed |
| KASICH COMPANY | MARKQUEST | undisclosed |
| AMERICAN LOGISTICS ASSOCIATION | MARKQUEST | undisclosed |
| MARKQUEST | MARKQUEST | undisclosed |
| TRACKONOMY SYSTEMS, INC. | ANCHOR & ARROW LLC | undisclosed |
| HOLLY STRATEGIES INC. ON BEHALF OF 202 GROUP | ANCHOR & ARROW LLC | undisclosed |
| CITY OF ST LOUIS | BRACY TUCKER BROWN & VALANZANO DBA BROWN & ASSOCIATES | undisclosed |
| EMAD EL SAID YOUSSEF SAAD EL-GALADA THROUGH BOLT CAPITAL, LP | NEXUSONE CONSULTING | undisclosed |
Source: Senate Lobbying Disclosure Act (LDA) filings, 2026
Top industries funding Carol Miller, ranked by total contributions.
Source: OpenSecrets.org (Center for Responsive Politics)
